MACULIGHT is a clinical-stage medical device study evaluating a home-based photobiomodulation therapy for patients with dry age-related macular degeneration (AMD). The therapy uses non-invasive light technology to stimulate retinal cell metabolism, potentially slowing disease progression and improving visual function. The 12-month multicenter study is currently enrolling participants at several German university eye clinics.
Funding
Funding not disclosed
Founders
Product
Problem
Dry age-related macular degeneration (tAMD) is a progressive retinal disease that leads to gradual vision loss, with limited treatment options available to slow its progression. Current therapies often require frequent clinical visits, creating a burden for elderly patients and limiting consistent, long-term management of the condition.
Solution
MACULIGHT provides a home-based photobiomodulation (PBM) therapy device designed to stimulate mitochondrial activity in retinal cells, reduce inflammation, and potentially improve visual function in patients with dry AMD. The therapy is prescribed by an ophthalmologist, with patients trained to use the device independently at home three times weekly. A 12-month multicenter clinical study is currently evaluating the device's efficacy and safety, with regular follow-up examinations at participating study centers to monitor patient progress and outcomes.
Target Audience
Primary target audience is patients diagnosed with dry age-related macular degeneration who are seeking non-invasive treatment options, as well as ophthalmologists and clinical research centers specializing in retinal diseases.
Features
- Non-invasive PBM technology that delivers specific light wavelengths to stimulate retinal cellular metabolism
- Home-use design enabling patients to perform treatments independently without medical supervision
- Structured 12-month study protocol with regular follow-up visits at partner eye clinics
- Free participation for eligible patients, including all study-related examinations and the MACULIGHT device
- Supported by published research including the Lightsite I, II, and III studies on multiwavelength photobiomodulation in dry AMD